Insider trade

Director sold ~$303K of CSTL shares in the open market

Traded Sep 21, 2026 · Filed Sep 24, 2026

Why it stands out

A Castle Biosciences director sold $303K of Castle Biosciences shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Director$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$303,166

Shares × reported transaction price

Timing vs results

53 days after results of Jul 30, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026.
This transaction was executed in multiple trades at prices ranging from $35.020 to $35.665, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Filed yesterday

Traded Oct 1 · filed 5 days later

Derivative exercise or conversion — not an open-market buy.

Planned saleFiled yesterday

Planned saleFiled yesterday